PFE

Pfizer just put Q3 2026 on the table and the first instinctive verdict from traders was a modest nod, with the stock up about 2.6% to roughly $30.80 after the release.

If Pfizer sat on your watchlist instead of in your portfolio, the past few months may feel like a missed call. Holding Pfizer from the start of the year would have returned 28.6%, including dividends.

The drugmaker increased its revenue and earnings forecasts while outlining additional cost reductions and upcoming pipeline milestones.

The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.

Pfizer CEO Albert Bourla says the company can replicate its past success as it leads a renewed push into the weight-loss drug market.

CNBC's Final Trades: Brown picked Amazon, Lebenthal chose BlackRock, Snipe backed Eaton, and Terranova recommended Pfizer.

Pfizer Inc (PFE) lifted full-year 2026 revenue guidance to $62--$64 billion and adjusted EPS to $2.95--$3.05, as non-COVID products grew 7% operationally and launched and acquired products surged 32%.

Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.